

Infigratinib: Adis Evaluation

Key Points

- A tyrosine kinase inhibitor is being co-developed by QED Therapeutics and Helsinn for the treatment of cholangiocarcinoma, urothelial carcinoma and other fibroblast growth factor receptor (FGFR)-driven conditions
- Received its first approval on 28 May 2021 in the USA
- Approved for use in previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a *FGFR2* fusion or other rearrangement

Summary

Infigratinib (TRUSELTIQ™), a fibroblast growth factor receptor (FGFR)-specific tyrosine kinase inhibitor, is being co-developed by QED Therapeutics and Helsinn for the treatment of cholangiocarcinoma, urothelial carcinoma and other FGFR-driven conditions.

Infigratinib was recently approved in the USA for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a *FGFR2* fusion or other rearrangement as detected by a test approved by the US Food and Drug Administration.

This article summarizes the milestones in the development of infigratinib leading to this first approval for advanced cholangiocarcinoma.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2021.